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Aim of the study: 
 To assess the feasibility of Hybrid conformal technique in treatment of 
Esophageal cancers thereby achieving a non inferior dose distribution, to reduce 
the volume of lung treated, and also to calculate the time taken for both. 
Materials and Methods: 
 Twenty  patients with carcinoma Esophagus were taken and their 
treatment plans were analyzed. All the patients underwent baseline pulmonary 
function tests, and compared with the same after treatment. The CTV,PTV, 
spinal cord, heart, and the lungs were contoured and planned.  Patients were 
treated with hybrid technique that combines CT based 2-opposing AP/PA 
technique and conformal beams. They were compared with the all-IMRT plans. 
Dose volume histograms were calculated for the planning target volume, heart, 
and lungs. Lung volumes were drawn with volume of the lung receiving 30 Gy 
(V20) and the mean lung dose (MLD) were calculated. The time taken for the 
all-IMRT and Hybrid-conformal techniques were calculated. 
 
Results: 
 Analyzation of both the techniques showed that, taking into account, the 
constraints for organs at risk, and given the full dose to the planning target 
volume, the dose distributions achieved was not inferior to that achieved in all 
IMRT plans. Dose volume histograms revealed that V20 and mean lung dose 
was lower in Hybrid conformal technique than all-IMRT plans, which was 
found to be statistically significant with a p-value of <0.05. The study also 
achieved cord and heart doses, as like the control plan. The time taken for 
Hybrid conformal technique was atleast 50% less compared to IMRT.  
Conclusion: 
 Hybrid conformal technique will be a good alternative with which dose 
distributions  achieved was not inferior to IMRT, along with reduction of both 
V20 and mean lung dose. The time taken for completion of treatment was also 
less compared to all IMRT plans, thereby leading to reduced treatment time. 
Reduction of lung doses might help in avoiding postoperative pulmonary 
complications like radiation pneumonitis, thereby improving the quality of life.  
Key Words:  
 Esophageal cancer, Hybrid conformal technique, IMRT, Two opposing 
and conformal therapy, Radiation pneumonitis, Treatment related pneumonitis. 
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1.INTRODUCTION: 
 
The esophagus is a hollow tubular structure, that bridges three 
compartments anatomically-neck, thorax and abdomen. It measures about 
approximately 25cm in length. It extends from the level of cricopharyngeus and 
extends upto gastro-esophageal junction. The esophagus is further divided into 
cervical and thoracic esophagus. The thoracic esophagus in turn, is divided into 
upper thoracic, middle thoracic and lower thoracic esophagus. The cervical 
esophagus extends from cricopharyngeus muscle upto the level of thoracic inlet, 
approximately 18 cm from the incisors. The upper thoracic esophagus, extends 
from thoracic inlet upto the bifurcation of trachea (carina), approximately 18-
24cm in length from incisors. The middle thoracic esophagus, extends from 
carina, upto the level of inferior pulmonary veins, approximately 24-32cm in 
length from incisors. The lower thoracic esophagus, extends from inferior 
pulmonary veins, upto gastro-esophageal junction, approximately 32- 40 cm 
from incisors.  
Spinal levels: 
 The spinal levels for the same classification is divided as , cervical 
esophagus from C7 to D3, upper thoracic esophagus, extending from D3-D5, 
middle thoracic esophagus from D5-D8, and lower thoracic from D9-D11 
vertebrae.  
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Siewert et al Classification:  
Siewert classified Adenocarcinoma of the gastro-esophageal junction, 
which often presents as a challenge for classification into esophageal or gastric 
cancers. The classification is based on demographics, histopathological 
variables, and also patterns of lymphatic spread. Based on these factors, Siewert 
et al classified OG junction tumours into three types: Type I tumours are those 
adenocarcinomas of the distal esophagus which often arises from an area which 
has intestinal metaplasia i.e. Barrett's esophagus, which may infiltrate the 
esophagogastric junction from above.  
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Type II tumours are those carcinomas that arise from the gastric cardiac 
epithelium or short segments with intestinal metaplasia at the esophagogastric 
junction. These tumours are also called as junctional carcinomas. Type III 
tumours are those that arise from subcardial gastric region which infiltrates 
gastroesophageal junction and distal esophagus from below. This was the 
original Siewert classification that was introduced in 1996. This classification 
was based on location of tumour and morphological characteristics.  
 
International Gastric cancer association (IGCA) and the International 
society for Diseases of the Esophagus (ISDE) consensus conference that held in 
1998, agreed that,  the classification outlined above should form the basis for 
defining of disease, assessing the severity and reporting the results of  treatment 
of adenocarcinoma that arises from the vicinity of gastroesophageal junction.  
 
This classification was modified later by C.J.Shearer for classifying 
tumours conveniently. This was later known as Modified Siewert's classification 
that is being followed widely. This classification classifies tumours as Type I 
starting >1cm upto 5cm above the OG junction (Z line), and are known as Type 
I adenocarcinoma of the esophagus. Type II extends within 1cm from OG 
junction extends upto  2cm caudally. Type III tumours extends more than 2cm 
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upto 5cm distally from OG junction. Type II and Type III are classified as 
gastric cancers.  
 
 
 
AJCC classification: 
On the contrary, the recent classification given by American Joint 
committee on Cancer (AJCC), divides the esophagus as Cervical, which extends 
from the level of cricopharyngeus (C7 or 15cm from incisors), upto the level of 
thoracic inlet (approximately T3 or 20cm from incisors). The thoracic 
esophagus extends from T3 to T10 or T11. The upper thoracic esophagus 
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extends from thoracic inlet upto the level of lower border of azygous vein, 
extending approximately 20-25cm in length. The middle thoracic esophagus, 
extends from lower border of the azygous vein, upto the level of inferior 
pulmonary veins, extending 25-30cm from the level of incisors. The lower 
thoracic esophagus extends from the inferior  pulmonary veins upto the level of 
stomach, inclusive of gastroesophageal junction. The Gastroesophageal junction 
can be accurately distinguished by means of squamo-columnar junction. The 
most recent classification also mentions that, if cancers having an epicentre, 
either in the lower thoracic esophagus, gastro-esophageal junction, or 5cm into 
the proximal stomach extending onto the gastro-esophageal junction or 
esophagus, are classified as Adenocarcinoma of the esophagus. If the epicentre 
is more than 5cm distal to the OG junction, or within 5 cm but not involving the 
OG junction, then they are classified as stomach cancers. Moreover, Siewert 
classification is disregarded in the latest AJCC classification.  The AJCC 
classification is based  on adjacent surgical landmarks.  
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Lymphatic Drainage: 
The nodal system that drains the esophagus is essential in understanding 
the treatment approaches directed towards the various sublevels. Tumours of the 
cervical and upper thoracic esophagus, drains into cervical and superior 
mediastinal lymph nodes.Tumours of the middle third of esophagus drains both 
proximally and distally, and drains into paratracheal, hilar, subcarinal, 
periesophageal and pericardial nodes. Tumours present in the lower third of 
esophagus, drain mainly towards lower mediastinum and celiac nodal basins.  
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Due to the extensive lymphatic network, and  because of the rich mucosal 
and submucosal drainage in the wall of esophagus, skip metastases are 
common. Tumours in the cervical and upper third can metastasize to celiac axis, 
and distal tumours can spread to cervical lymph nodes.  In addition, around 71% 
of the frozen sections show negative margins, but show lymphatic 
micrometastases by immunohistochemistry . These nodal drainage usually drain 
following their arteries;  viz inferior thyroid, esophageal, bronchial or the celiac 
axis. 
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Lymphnode involvement in percentage in various subsites:  
Nodal 
drainage 
Cervical 
(%) 
Upper 
thoracic(%) 
Mid 
thoracic(%) 
Lower 
thoracic(%) 
Cervical 14.2 8.0 6.2 5.2 
Mediastinal 11.1 85.2 50.7 66.0 
Abdominal 2.8 31.9 45.5 92.7 
 
Radiotherapy: 
The design and delivery of radiation therapy involves appropriate 
knowledge of the natural history of disease, anatomy, disease extent and nodal 
involvement, patterns of failure, and radiobiologic principles. Further, the use of 
proper equipment, implementation of methods to decrease treatment associated 
toxicity, proper coordination with the physicist and technological staff are 
essential.   
 
General Techniques:  
Depending on the primary tumour, there may be a number of sensitive 
organs that might come inside the radiation field. These include, which not only 
limited to , spinal cord, lungs, heart, intestine, stomach, kidney and liver. Hence, 
it is essential to reduce the dose to the normal structures to the utmost 
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minimum, without compromizing the dose to the primary tumour and the loco-
regional lymph nodes. These may be aided by means of simulation, CT 
planning and dose-volume histograms.  
 
Conventional Therapy: 
The target volume should include the primary tumour as defined by 
barium swallow and oesophagoscopy. It should include margins of about 5cm 
proximally and distally with the length not exceeding 18cm. The lateral margins 
should be enough to encompass the soft tissues surrounding the oesophageal 
wall (usually 6cm) or 8cm if adjacent nodes involved are to be included. In 
older patients, the superior and inferior margins can be reduced to limit the 
severity of acute radiation reaction.  
 
Anatomical factors like spinal cord, lungs, heart, anterio-posterior 
diameters constrain the delivery of homogenous dose distribution to the 
esophagus. The changing postion of esophagus during its course, along with the 
variation of the contour of the body, often leads to the plane of treatment be 
inclined, rather than parallel to the couch. It should be borne in mind, that the 
created volume will be cylindrical in shape. The dose to the spinal cord and 
lungs should be reduced as much as possible.  
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The technique for the cervical and upper third of esophagus will include 
both the primary tumour and the supraclavicular lymph nodes. Various designs 
are possible and depends on the geometry of tumour and their relation to the 
spinal cord. The ideal design would be to design a three field technique that 
involves an anterior field and two posterior oblique fields. However, since the 
primary tumour is rarely midline, it is better to design with antero-posterior 
(AP) and postero-anterior fields (PA) to 39.6 and 41.4 Gy followed by right or 
left opposed oblique pair with photons to deliver upto 50.4Gy. Since this 
technique will exclude the supraclavicular fossa, a separate electron field is 
added to deliver at a depth of 2-3cm depending on the patient's anatomy, 
delivering thereby upto 50.4Gy. For middle and lower thoracic tumours, the 
same wedged single anterior and two posterior oblique fields are used.  
 
Simulation:  
The patient is placed supine with the hands resting above the head. Thin 
barium is used and the patient is advised to swallow the same. This helps in 
delineating the upper and lower borders of the field. Having defined the upper 
and lower limits of the field, and the width of volume, the patient is simulated 
from the side to define the depth in the anteroposterior plane. The field is 
inclined to exclude the spinal cord. It may not be possible always to exclude the 
spinal cord if the dose to the primary tumour should not be compromised. 
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During such cases, not more than 1cm of the cord should be included in the 
treatment volume. The posterior oblique fields are viewed to assess adequate 
coverage. Contours are taken through the top, middle and bottom of the volume. 
The positions of the spinal cord, heart, lungs and the tumour volume are 
measured. A correction should be done for the transmission of radiation through 
the lungs. ( Usually, 3% per centimetre of lung traversed). The beam passing 
through the lung will give 30-40% higher dose to the oesophagus, than the same 
beam through the solid tissues. The dose to the spinal cord should not receive 
more than 40 Gy in 4 weeks.  
 
Conformal therapy: 
Three dimensional conformal therapy links 3D CT visualization of the 
tumour with the linear accelerator capable of shaping the beam both 
geometrically and by means of altering the fluence (Intensity modulated 
radiotherapy). 3D CRT encloses the target volume as close as possible and with 
minimizing the dose to the adjacent normal structures. The radiation oncologist 
as well as the physicist agree to the final planning target volume (PTV) which 
has been created by means of 3D growth algorithms, and protocols followed in 
the department, keeping in mind the organs at risk (OAR). This ensures 
understanding of the tumour cell density pattern within the PTV, homogeneity 
of dose distributions, dose constraints to adjacent OAR, avoidance of maximum 
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and minimum dose spots, and review of beam arrangements. Basic conformal 
radiotherapy consists of coplanar and static beams with the multileaf collimators 
(MLCs) or cerrobend blocks shaping the tumour volume.  For coplanar non 
standardconfiguration of beams, Dose volume histograms (DVH) may aid in 
selecting the best plan; but it will not show whether the organ at question will 
receive a high or low dose. DVH of the CTV, PTV, PRV are all required to 
clinically correlate and arrive at the precise outcome. Selection of the final plan 
is made after scrutinizing the PTV and DVH. Good communication is important 
between radiation oncologist, physicists and the technical staff in ensuring no 
transfer or setup errors while delivering the treatment.  
 
Conformal therapy involves the use of mixed beams like photons and 
electrons, and then the beams are modified using bolus, wedges, compensators, 
MLCs, shielding blocks. Optimization of skin dose is achieved by  skin sparing 
using higher megavoltage energies, or by maximising skin dose with tissue 
equivalent material.  Higher dose energy beams are used in treating pelvic 
patients,  and lower dose is used for breast and head and neck treatments in 
adjusting skin dose to tumour dose as necessary.  
 
Based on the tumour consensus and other patterns of spread data 
available for squamous cell carcinomas of esophagus, general guidelines for 
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field design can be as follows. For cervical and upper thoracic esophagus, the 
CTV encompasses nodal basins from the lower cervical region including the 
supraclavicular fossa superiorly uptosubcarinal region inferiorly including the 
upper paraesophageal lymph nodes. For lower esophageal squamous cell 
carcinomas, lymph nodal basins from subcarinal region superiorly to the left 
gastric and common hepatic artery / celiac lymph nodal basins inferiorly.For 
middle esophageal tumours, field design should be individually tailored 
according to the tumour and complete coverage of paraesophageal nodal basins 
are necessary.  
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In the field design, potential nodal involvement and therefore, the target 
volumes may be problematic. Most reports state that more than 15% of 
metastatic nodes are 1cm away and that there is no obvious size difference 
between involved and uninvolved nodes. To add to this scenario, FDG-PET is 
only about 67% sensitive in detecting nodal metastases. Even, Endoscopic 
Ultrasound (EUS), which is considered as most sensitive  in picking up 
lymphatic metastases, detects only about 75% of cases. Hence, these tests 
should not be relied upon exclusively for defining planning target volumes and 
understanding the nodal drainage is much important. 
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The field design for adenocarcinoma of esophagus, is similar to the lower 
thoracic squamous cell carcinoma, and deserves a special mention. 
Periesophageal lymph nodes are generally included for all patients. Because 
lymph nodal involvement is associated with more depth of penetration of 
tumour i.e T stage, and because gastroesophageal junction tumours are usually 
more advanced, inclusion of celiac lymph nodal basins for distal esophagus and 
OG junction tumours are usually indicated.  Studies done by Erlangen et al 
shows some specific considerations. They are 
 Lymphovascular invasion is predictive of nodal spread.  
 Proximal extension of tumours beyond the Z line, and distal spread in type II 
and type III tumours predicts an increasing evidence of paraesophageal 
lymph nodal involvement.  
 Estimated nodal incidence cut-off of 20% for inclusion has special 
considerations including: 
 The lower paraesophageal, paracardial, lesser curvature, left gastric 
artery nodes should be included in the CTV. 
 The presence of lymphovascular invasion predicts a nodal spread 
of more than 20% in left and right gastroepiploic, greater 
curvature, celiac trunk and splenic hilar regions.  
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 In T3/T4 disease, the gastroepiploic,  greater curvature, celiac 
trunk, splenic hilar, splenic artery, common hepatic artery should 
be included.  
 High grade tumours should include left gastroepiploic, greater 
curvature and celiac nodes should be included.  
 Larger and deeply penetrating tumours should also encompass 
splenic hilar, splenic artery and also nodes along greater curvature.  
 Tumour extending above diaphragm and those exteding more than 
1.5cm beyond the Z line should include midesophageal nodes upto 
carina. It should be borne in mind, that such extensive field will 
lead to potential side effects and hence the fields should be decided 
based on individual build and anatomy of the patient.  
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A margin of 5cm above and below the GTV with a 2.0-2.5cm radial 
margins are usually given to cover the submucosal and nodal disease. Because 
of the uncertainty of daily setup errors, and physiological organ motion ( like 
peristalsis, respiration, cardiac motion), additional margin is given to the CTV, 
especially to the mobile distal esophagus. More recently, the Internal Target 
volume (ITV) is used to account for physiologic motion of the organs, which is 
usually encompassed in the PTV. Varying reports show that esophageal motion 
varies anteriorly and posteriorly from 0.1-4mm, lateral motion ranging from 
0.3-4.2mm, and superior-inferior motion ranges from 3.7 to 10mm. An analysis 
evaluating interfractional right-left and anteroposterior movement shows that 
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left to right motion ranges from 1.8 to 5.1mm favouring leftward movement; 
and anteroposterior motion ranges from 0.6 to 4.8mm favouring posterior 
movement. It was concluded that 12mm left, 10mm posterior, and 9mm anterior 
margins are appropriate.  
 
Intensity Modulated Radiotherapy:  
IMRT is done using MLCs to define the beam intensity, independently at 
different regions of the incident beam, thereby producing the desired dose 
distribution uniformally, or deliberate non uniformal dose distribution within 
the target volume. The position of the leaves can be modified in time with a 
fixed or a moving gantry. IMRT can be delivered by means of: 
 Dose compensation 
 Multiple static fields 
 Step and Shoot technique 
 Dynamic MLC 
 Tomotherapy 
In the Step and shoot technique, the sequence of static beams are used with 
the beam switched off between changes in position.  In the dynamic MLC, there 
is automatic sequence of beam segments without stopping treatments. Other 
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methods like tomotherapy involves intensity modulated rotational delivery with 
the help of fan beams.  
 
Forward planned or Segmental IMRT, involves simple tissue compensation 
with the beams eye view of PTV and the subsegments are shaped with different 
MLC to create a uniformal dose distribution. Inverse planning requires dose to 
the PTV, CTV, OARs in terms of dose volume constraints, optimization of 
fluence, and 3D dose planning.  Careful quality assurance is must in assuring 
the accuracy of the beam. Dose delivery is verified throughout the course of 
treatment by using radiographic films or EPIDs. Accurate patient positioning, 
target volume delineation, reduction of organ and patient movements especially 
respiration, validates the use of safe and precise IMRT dose delivery.  
 
IMRT modulates the intensity of the beam and the geometric conformation, 
so that, it delivers complex dose distributions with the help of forward and 
inverse planning. Plans can be produced with concave shapes, and hence critical 
structures like spinal cord, etc can be spared better, thereby reducing the late 
toxicities of treatment. However, integral dose is higher, which is a drawback 
with IMRT, and hence increases the risk of development of second 
malignancies. IMRT with steep dose gradients, can lead to under dosage of 
tumour if margins are close and organ movements are present.  
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It is difficult to produce evidence of benefit for this new technology, until, 
wide randomized controlled trials are done to prove its superiority. Furthermore, 
the unwanted late effects of treatment cannot be predicted, and hence true 
efficacy of the treatment and to arrive at its therapeutic ratio, is delayed.  
 
Organs at Risk (OAR): 
The International Commission on Radiological Units (ICRU) defines 
OARs as those normal tissues, which lies adjacent to the tumour site, and may 
therefore be included in radiation fields,  with a risk that radiation might lead to 
its impaired functioning.  Hence, planning involves delineation of not only the 
tumour site, but also to avoid normal tissues.  
 
There is a caveat that, increasing awareness of organ motion and 
treatment delivery errors might lead to larger PTVs which might overlap normal 
structures.  In practice, the dose limits are usually applied to the organs at risk  
as defined on planning images. Among them, spinal cord serves as an 
exception, taking into account, the late effects of its toxicity, especially 
myelopathy and paralysis. The cord itself can be contoured, and a 3-5mm 
margins are added isotropically to create a PRV. Alternatively, the spinal canal 
can be contoured, which will automatically give a 0.3-0.5cm margin to the 
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OAR. Planning spinal canal is more advantageous, as it can compare the dose to 
that achieved in 2D planning, where spinal canal is always contoured.  
 
In Cancers of the Oesophagus, the organs at risk, usually involves the 
spinal cord, lungs and heart.  Hence, planning is done in such a way, that the 
cord dose is achieved, along with minimal doses to the lungs and heart.  The 
cord dose is important compared to other structures, as the late effect that might 
occur with spinal cord is usually catastrophic, which will affect the quality of 
life. The other OARs are taken into consideration to avoid the dose as much as 
possible, which will reflect in reducing complications with multimodality 
treatment that is available at present.  
 
Tolerance Doses: 
To assess the acute and late morbidity of normal tissues, that might be 
affected by radiation., tolerance doses need to be set for each and every organ. 
Correlating the risk of side effects with 2D planning, the TD 5/5 was generated 
which is still in use. This gives an estimate of about 5% probability for a given 
side effect to appear after 5 years of treatment. Similarly, TD 50/5 assesses the 
50% probability for a given effect to appear after 5 years of treatment.  TD will 
usually assess the point dose, which are useful in organs like spinal cord. It may 
not be of much use, when the organs taken into consideration are made up of 
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parallel subunits, and hence, 3D volumes are drawn to assess the volume of 
tissue receiving radiation dose, which can be assessed by means of Dose 
volume histograms.  
A dose-volume histogram plots radiation dose on the x-axis, and percent 
volume of structure of interest on the y-axis. The area under the curve and the 
shape of DVH is used to ensure homogenous dose is obtained for the target 
volume, with the dose received by the OARs is within acceptable limits. From 
this, the percentage of volume of dose received by the particular organ can be 
read as Vd.  
 
If DVH are obtained from series of patients in whom acute and late 
toxicities are recorded, then it may be useful to predict at what dose, these 
effects might occur. It must be borne in mind that these limits, essentially 
simplify the dose into a single value, and it must be correlated with doses from 
series of patients to arrive at a conclusion.  Quantec data is used to arrive at the 
dose constraint in a better manner.  
 
Clinical implications of QUANTEC AND EMAMI: 
Two of the most commonly used systems for calculating dose volume limits 
are the QUANTEC and EMAMI; which has some of its own implications.  
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 Dose- response curves are different for different organs, indicating that 
there may be different mechanisms for radiation induced damage in 
different organs, and hence the endpoints will vary depending upon the 
mechanism.  
 Some organs are considered to be in series; eg. spinal cord, small bowel 
and optic nerve, have a steep dose response curve beyond a critical dose 
threshold; and hence damage to a single functional sub unit can lead to 
dysfunction of entire organ. This is expected because of the anatomy and 
function of these organs.  
 Moreover, some of the neural structures like brain, brainstem, optic 
nerve, spinal cord have similar kind of mechanism, with a TD of 55-
60Gy, which corresponds to a Biologically equivalent dose of 100 Gy. In 
other words, it corresponds to an alpha/beta ratio of 3 Gy. As these 
structures are depending upon the vascular supply for each organ, it 
clearly implies that, vascular injury will be one of the most possible 
mechanisms for the above mentioned type of injury.  
 Some organs are considered to be in parallel, for eg. lung, liver, kidneys, 
parotid; experience radiation induced damage at lower doses, and have a 
gradual dose response curves in contrast to serial organs. This suggest 
that, the mechanism of injury that occurs in these organs are different, 
and one possibility is that, each functional subunit inside the organ 
behaves differently compared to the structures inside the neuronal tissues. 
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Hence, to conclude, all such organs like the nephrons, hepatocytes can be 
radiosensitive.  
 
 The concept of series and parallel is important, as the spinal cord has a 
serial component, and the lung has a parallel component. For example, in 
lung irradiation, doses to whole lung, if kept from 15 Gy to 23 Gy have a 
very low risk of developing symptomatic pneumonitis. On contrary, if it 
was heterogenous lung irradiation, then each lung behaves as a functional 
subunit, and hence, mean lung doses of 15 to 23 Gy to a single lung will 
have 10 % to 25 % chances of developing symptomatic pneumonitis. 
Hence, mean lung dose is just a tool to understand the percentage of lung 
receiving various doses of irradiation.  
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REPORTS CONTRIBUTIONS SHORTCOMINGS 
Rubin et al, 1975 Introduced TD 5/5 and TD 
50/5 
Minimal dose volume 
data 
Emami, 1991 Concise dose volume 
summary having most 
useful endpoints.  
Based on available clinical 
data and expert opinion. 
Limited data available.  
More expert opinion. 
QUANTEC, 2010 3D dose-volume/ outcome 
data. 
Systematic review 
addressing organ changes 
and confounding factors.  
Not all organs have 
dose-volume data. 
Hence, cannot be used 
everytime.  
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Individual Organ tolerances: 
Spinal cord: 
As the effect of late radiation damage to the spinal cord is irreversible 
paralysis, treatment modalities that include spinal cord have always been 
cautious; and there is paucity of clinical data, to base on estimation of spinal 
cord tolerance. Therefore, estimates for the spinal cord have always been 
conservative.  
 
The spinal cord should be either contoured as such, or given a 5mm 
margin to create the planning organ at risk volume (PRV). Dose to any part of 
the cord should be less than 46 Gy. If more than 15cm of the cord is treated, it 
should be less than 44 Gy. A small portion of the cord, may be 1cm can get a 
dose upto 50 Gy.  In cases where hypofractionation are used, the dose to the 
cord should be lowered to reduce the toxicities.  Other method is to calculate the 
point dose to the spinal cord, which should be less than 45 Gy.  
 
Lungs: 
Late fibrosis is best correlated with a V20 target value of less than 32% 
percent of the lung receiving less than 20 Gy. Mean lung doses are also used to 
calculate the constraints.  
27 
 
 
Risk of Second malignancies: 
Any radiation dose that is been delivered, will theoretically increase the 
chance of second malignancy, and hence, safe dose limits to radiation cannot be 
prescribed. In practice, the irradiated volume should be kept as small as 
possible. This is better achieved with the help of newer techniques like the 
IMRT and VMAT. Even if techniques like IMRT, gives a better dose constraint 
to normal tissue, it delivers a higher integral dose, and hence, irradiates larger 
volume of normal tissue.  This in turn, leads to increased risk of second 
malignancy. The long term data for IMRT is not available, and studies 
collaborate the risk only from biological modelling. The risk of second 
malignancies in Hodgkins lymphoma receiving mantle field radiotherapy, was 
estimated to be around 30% at the end of 30 years. Hence, long term follow up 
is necessary to conclude the best results of newer techniques.  
 
Dose limits: 
OARs: 
 Spinal cord: Point dose of 45Gy 
 Lung:  V20 <30% 
                       TD 5/5: 45 Gy (1/3), 30 Gy (2/3), 1750cGy (3/3) 
                       TD 50/5: 65 Gy (1/3), 45Gy(2/3), 2450 cGy (3/3) 
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 Heart: V30 <46% 
                        TD 5/5: 60Gy (1/3), 45 Gy(2/3), 40 Gy (3/3) 
                        TD 50/5: 70Gy(1/3), 55 Gy(2/3), 50Gy (3/3) 
                        Mean dose <26 to 30 Gy 
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2.REVIEW OF LITERATURE: 
Radiation Therapy alone: 
There are no studies comparing surgery vs radiotherapy as a sole 
modality of treatment. Radiation therapy alone is given in places where 
treatment is palliative and lesions are deemed inoperable because of the tumour 
extent and other contraindications. In general, those who receive radiation alone 
have a median survival of six to twelve months and a 5-year OS of <10%.  
 
A meta-analysis of 49 series  consisting of more than 8400 patients,  
treated with only radiotherapy, found overall survival at 1, 2 and 5 years to be 
18%, 8% and 6% respectively. Hancock and Glatstein (7) reviewed around 
9500 patients and found only 5.8% to survive at the end of 5 years. Another 
study by Okawa et al reported stagewise 5 year survival rate. For Stage I, 5 year 
OS was 20% , Stage II 10%, Stage III 3%, and Stage IV 0% with an overall 
survival rate at 5 years to be 9%. Lederman treated 263 patients with radiation 
therapy alone and reported 3-year and 5-year survival rates of 11% and 7% 
respectively.  
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Neoadjuvant Chemoradiation: 
Preoperative radiotherapy to esophagus have some potential advantages: 
 Increased resectability of tumours 
 Increased radioresponsiveness secondary to increased tumour 
oxygenation 
 Theoretical decrease in dissemination during surgery 
 Avoidance of surgery in patients with rapidly progressive disease.  
 
Walsh et al: 
This study (8) compared the role of concurrent preoperative 
chemoradiation combined with surgery.  A total of 110 patients of 
adenocarcinoma of esophagus were randomized to receive cisplatin, 5-FU, and 
concurrent radiation therapy followed by surgery vs surgery alone. Combined 
modality involved chemotherapy at weeks 1 and 6 followed by radiation 
therapy which included an anteroposterior  and then changed to three field  
technique to  a total dose of around 40 Gy in 15 fractions. Surgery was 
performed four to six weeks later. Median survival was 16% with preoperative 
chemoradiation therapy vs 11% with surgery alone. The 1, 2 and 3 year survival 
was 57%, 37% and 32% with multimodality therapy compared to 44%, 26% 
and 6% for surgery. Even though, the study concluded 
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neoadjuvantchemoradiation showed superior results, it was criticized for its 
poor surgery alone results, lack of follow-up and historical controls.  
 
Urba et al: 
This study (9) reported the results of 100 nonmetastatic esophageal 
cancer patients with squamous  and adenocarcinoma histologies by comparing 
concurrent chemoradiation followed by surgery vstranshiatalesophagectomy 
alone. Chemotherapy regimen consisted of cisplatin, 5-FU, and vinblastine. 
Radiation included dose of 1.5Gy per fraction twice daily for three weeks to a 
total dose of 45 Gy followed by surgery on day 42. Tumours more than 5cm, 
Age more than 70 years, and squamous cell histology were associated with poor 
survival. There was no statistical difference at the end of 8 years, but the three 
year survival showed 30% vs 16% benefit respectively. There was reduced local 
recurrence with the results inclined towards concurrent chemoradiation 
followed by surgery (40% vs 16%), although the sample size was very small 
and hence could not be made as standard of care.  
 
EORTC trial: 
Bosset et al (10) randomized 282 patients with thoracic esophageal 
squamous cell carcinoma to either surgery or preoperative concurrent 
chemoradiation followed by surgery. Patients were treated with split course 
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radiotherapy, with a two weeks interval, giving 3.7 Gy to a total of 37 Gy. The 
study showed higher postoperative complications of about 12% compared to 
preoperative mortality of 4%. Also, there was disease free survival, negative 
margins, cancer related mortality and local control with neoadjuvant 
chemoradiation, but there was no overall survival. The study also concluded 
that higher dose per fractionation had a detrimental effect with wound 
morbidity.  
 
CROSS trial: 
One of the largest randomized controlled trials (11) that compared 
neoadjuvantchemoradiation followed by surgery versus surgery is the CROSS 
trial, or the Chemoradiotherapy for Oesophageal cancer followed by Surgery 
Study. This study included resectable tumours who received Chemotherapy 
with Paclitaxel 50 mg/m2 weekly with Carboplatin (AUC-2), along with 
radiotherapy to a  total dose of 41.4 Gy followed by surgery versus surgery 
alone. R0 resection was seen in 92% of patients in the chemoradiation arm 
versus 69% in surgery arm. Pathological complete response is seen in 29% of 
patients with chemoradiation. Median survival was 49 months in 
chemoradiation arm versus 24 months in surgery arm. The 3-year overall 
survival was 58% and 44% respectively.  This study concluded that there is 
significant overall survival with preoperative chemoradiation, and the only 
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study to show the same, and hence can be considered as the treatment of choice 
for esophageal cancers. 
 
Preoperative chemoradiation versus Preoperative chemotherapy: 
German study group compared neoadjuvant chemoradiation with 
neoadjuvant chemotherapy by means of POET trial (Preoperative 
Chemotherapy or Chemoradiotherapy in Esophagogastric Adenocarcinoma). 
This study (12) randomized patients into two groups- first arm were randomized 
to receive cisplatin/ 5-FU based chemotherapy alone and second arm received 
similar induction chemotherapy followed by concurrent cisplatin/etoposide with 
30Gy radiation therapy. This study was terminated earlier due to poor accrual.  
Even so, this study indicated that patients who were randomized to receive 
preoperative concurrent chemoradiation had: 
 Higher N0 rates (64% vs 37%)  
 Pathological complete response (16% vs 2%) 
 Improved local control (76% vs 59%) 
 3-year overall survival (47% vs 28%) 
Hence, the study concluded that preoperative chemoradiation had a better 
overall survival in locally advanced esophagogastric adenocarcinoma.  
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Chemoradiationvs Radiation: 
RTOG 85-01: 
 
This is one of the landmark trials that compared definitive 
chemoradiation against radiation therapy alone.  Herskovic et al (13) 
randomized patients to receive radiation only to a total dose of 64Gy versus 
chemoradiation with a total dose of 50 Gy along with cisplatin and 5-
Fluorouracil. Even though, chemoradiation arm received less dose of RT, there 
was significant advantage for the same, with a median survival of about 12.5 
months for the chemoradiation arm vs 8.9 months, along with a 2-year survival 
rate of about 38% vs 10%. Local recurrence was decreased from 24 to 16 % and 
and two year distant metastates was reduced from 26% to 12%. The study was 
stopped in between due to this high significant survival difference, and patients 
in radiation arm were transferred to chemoradiation arm. Updated results 
indicate 5-year overall survival rate of 26% vs 0%. Local recurrence was about 
45%  in chemoradiation arm vs 69% in radiation only arm; and distant 
metastases were 12% vs 40% respectively. Although there was statistical 
difference with chemoradiation, the rates of acute toxicity, including incidence 
of life threatening side effects of radiation like hematologic toxicity and fistula 
formation were more with concurrent chemoradiation versus radiation. Hence it 
was concluded that, local control, median and overall survival were better with 
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chemoradiation arm compared to radiation only arm, at the cost of increased 
side effects.  
 
INT 0123 (RTOG 94-05): 
This study randomized 236 cases of stages T1-4 N0-1M0 squamous or 
adenocarcinoma to either high dose radiation 64.8 Gy versus 
50.4Gychemoradiation. Chemotherapy consisted of cisplatin and 5-
Fluorouracil; Radiation field included superior and inferior margins of about 
5cm above and below the tumour upto a TD of 50.4 Gy, followed by tumour 
boost to about 64.8 Gy with a 2cm margin above and below the tumour. No 
difference was found between high and low dose arms in median survival (13 vs 
18 months), 2-year overall survival (31 % vs 40%) or local recurrence (56% vs 
52%). It was noted that there was higher treatment related mortality with high 
dose radiation arm, but the same occurred before 50.4 Gy. Hence, the finding 
was found to be controversial.  
 
Chemoradiation vs Chemoradiation followed by Surgery: 
French study: 
This study (14) randomized 445 patients, who were having clinically 
resectable tumours, involving both squamous and adenocarcinomas.  All 
patients received cisplatin and 5-FU. Radiation were given as either 46 Gy over 
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4.5 weeks (continuous) or 30 Gy over two weeks with 15 Gy per week (split 
course). Among them, 259 patients who had partial response, were either 
randomized to surgery or additional chemoradiation with cisplatin and 5-FU. 
There was no significant difference between median survival (18 vs 19 months),  
2 year survival (34% vs 40%) but the 2 year overall survival was better with 
surgery( 67% vs 57%). The death rates were 9% with surgery arm and 1% with 
chemoradiation arm, along with a worse quality of life. The study concluded 
that, surgery in responding patients does not improve survival.  
 
German study: 
Another study (15) from Germany randomized 172 cases of potentially 
resectable squamous cell carcinoma of the esophagus with 5-
FU,leucovorin,etoposide  and cisplatin for three cycles followed by concurrent 
cisplatin and etoposide with 40Gy of External beam radiotherapy. The patients 
were further randomized to receive either surgery or additional 
chemoradiotherapy where the dose of radiation is increased to either 60 or 65 
Gy, with or without brachytherapy. Although, there was increased local control 
in surgery arm, there was no overall survival between the two arms, and also, 
surgical arm was associated with severe postoperative complications (70%) and 
overall hospital morbidity rate of about 11%. It was found in regression 
analysis, that tumour response to induction chemotherapy was the only 
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prognostic factor. The only drawback of this trial was that around two-thirds of 
patients in surgery arm alone had surgery. The authors concluded that surgery 
only improves local control and not overall survival; and also, those patients 
who did not respond to induction chemotherapy might benefit from surgery,and 
hence apt tumour response should be noted and patients should be treated 
according to the same.  
 
Adjuvant Chemoradiation: 
North American Intergroup trial 0116: 
This study was done to evaluate the efficacy of Postoperative adjuvant 
chemoradiation in locally advanced gastric and OG junction tumours. The study 
randomized 556 patients with the above mentioned malignancies to either 
surgery or surgery combined with postoperative chemoradiation.  The 
multimodality treatment arm included  5-FU/ Leucovorin combined with 
radiotherapy to a total dose of 45 Gy followed by additional two cycles of 5-FU/ 
Leucovorin. Median overall survival was found to be 36 months vs 27 months 
favouring chemoradiation given after surgery. Also, the three year overall 
survival was 50 % in postoperative chemoradiation against 41% with surgery 
alone.  
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Brachytherapy: 
Gaspar et al (16) examined and reported the results of intraluminal 
brachytherapy in patients with non-operable esophageal cancer in a randomized 
controlled prospective trial. Patients in this study, received 50 Gy of External 
beam radiotherapy followed by a two week break followed by brachytherapy. 
Patients then are randomized to either 15 Gy of High dose rate (HDR)  
brachytherapy in three fractions of 5 Gy each; or a single fraction of 20 Gy low 
dose rate (LDR) brachytherapy in a single fraction. The dose was then 
prescribed at 1cm from the source axis. Brachytherapy was accomplished by 
means of using 10- or 12-size French applicator, inserted through transnasally 
or transorally. The target length was defined by means of tumour length with a 
1cm proximal and distal margin, which is measured by means of computed 
tomography, barium swallow, and endoscopy.  Both external radiation and 
brachytherapy were given concurrently with 5-FU chemotherapy. The dose in 
HDR arm was reduced to 10 Gy in two fractions due to the development of 
fistulas in two patients. The LDR arm was closed because of poor accrual.  
There was a 11 month median survival in both arms. Local residual disease or 
recurrence was found in 63% of 49 patients treated, and six patients among 
them had developed esophageal fistulas. Among these six patients, three 
patients, had treatment related deaths. It was found that there was 18% chance 
of developing fistula at the end of one year. Other studies showed fistula 
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development rate of about  0-12%. It was concluded that, concurrent 
chemotherapy along with brachytherapy have increased morbidity, and should 
be approached with extreme caution depending on the patient.  
 
Brachytherapy as a palliative modality: 
Most of the advanced non-operable esophageal cancer patients, present with 
total dysphagia. To relieve the same, either a metallic expanding stent or 
brachytherapy is commonly used. Danish study compared the results of 
palliation for endoscopic stent placement versus single dose HDR 
brachytherapy. This study randomized 209 patients, and the exclusion criteria 
were as follows:  
 Tumours more than 12 cm.  
 Tumours within 3cm of upper esophageal sphincter 
 Deeply ulcerated tumours 
 Tracheo-esophageal fistula 
 Tracheal involvement 
 Patients with pacemakers 
 Patients with stent placement 
 Patients treated with radiation treatment 
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Brachytherapy was delivered by means of a 1-cm flexible applicator  
through which a single fraction dose of about 12 Gy is delivered, which is 
prescribed at a distance of 1cm from the source axis. This study showed that, 
patients who had stent insertion  had a immediate relief for dysphagia, but on 
the long run,  those patients who received brachytherapy, had a long term relief 
from dysphagia compared to endoscopic stent placement. Also, complication 
rates were higher, including bleeding from stent placement in stent arm vs 
brachytherapy arm (33% vs 24%).  
 
Toxicities:  
Postoperative complications: 
 Pulmonary complications 
 Cardiac morbidity 
 Leak at anastomotic sites 
 Recurrent laryngeal nerve paralysis 
 Stricture formation (14-27%) 
Radiation induced Toxicity: 
Acute Toxicities:  
 Esophagitis 
 Dysphagia 
41 
 
 Neutropenia 
 Thrombocytopenia 
 Epidermiditis 
 Fatigue 
 Weight loss 
 Nausea 
 Vomiting 
 
Some of the life threatening complications in addition to above are 
Perforations of esophagus, which presents with retrosternal pain, fever, thready 
pulse, shock, hemorrhage, etc. The addition of chemotherapy increases the risk 
of side effects mentioned above, atleast increasing in about 50-70% of patients. 
In fact, the risk of grade 3 toxicity increases to about 44% compared to 25% 
with radiation therapy alone. Grade 4 toxicity  is shown to be 20% with 
concurrent chemoradiation in contrast to 3% with radiation therapy alone. The 
percentage is less, because the number of patients with such toxicities may not 
survive the same.  
 
Late Toxicities: 
The most common late effects associated with radiotherapy are stenosis 
and stricture formation. Dysphagia associated with stenosis and stricture occurs 
in about 10-15% of patient, and  can be relieved by Savary-Gilliard dilatation, 
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as a temporary basis. Usually three to four dilatations will be required. RTOG 
trial showed that long term side effects especially Grade 3 toxicity are nearly 
equal with both concurrent chemoradiation and radiation therapy (29% vs 23%). 
However, Grade 4 toxicities are more with concurrent chemoradiation arm 
(20%) versus radiation arm (3%).   
 
Radiation pneumonitis: 
One of the most common under reported complications is Radiation 
pneumonitis. It can range from minimally symptomatic to fatal disease. The 
most common presenting features are non productive cough, dyspnea, 
respiratory distress, etc; which occurs mostly after two to six months of 
radiation therapy. Some of the most common predictive markers to assess lung 
toxicities are V20 > 30 percent, mean lung dose of more than 20 Gy, V5 of 
more than 42%,  or an absolute V5 of more than 3000 sq.cm.  
 
  
43 
 
Grading:  
Radiation Therapy Oncology Group Criteria (RTOG)(17): 
Acute: 
Grade 0 No change 
Grade 1 Mild symptoms like dry cough and dyspnea on exertion 
Grade 2 Persistent cough requiring narcotics/antitussives; dyspnea 
with effort but not at rest. 
Grade 3 Severe cough requiring antitussives, dyspnea at rest, 
Radiological changes of patchy pneumonitis, might 
require steroids or oxygen. 
Grade 4 Severe respiratory compromise requiring assisted 
ventilation. 
 
Late: 
Grade 0 No change 
Grade 1 Mild symptoms like dry cough with mild changes 
radiologically 
Grade 2 Moderate symptoms like fibrosis and pneumonitis. 
Presents with severe cough, patchy radiological 
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changes, fever 
Grade 3 Severe fibrosis, Dense radiological changes 
Grade 4 Severe respiratory insufficiency,  continuous assisted 
ventilation with oxygen. 
Grade 5 Death  
 
 
Trials from Japan, showed that, in patients (18) treated with concurrent 
chemoradiation with cisplatin and 5-FU, reported an incidence rate of 27%. The 
study also concluded that risk of radiation pneumonitis can be judged when V20 
was more than 30%. Similarly, in a study done by MD Anderson Cancer Center, 
101 patients were studied which included both operative and nonoperative 
patients having distal esophageal/gastroesophageal junction tumours who 
underwent a combination of both 3D CRT and IMRT, reported a risk of 59% , 
5%  and 1% of grade 2, 3 and 5 radiation pneumonitis respectively. On similar 
aspects, another study from Japan took into account, patients treated with 
Supraclavicular, mediastinal and celiac regions in both younger and older 
patients. The study reported that there was about 29% risk of cardiopulmonary 
toxicities in older (>75 years) patients compared to only 3% in younger patients. 
Hence, the study concluded, that older patients  may not tolerate extensive 
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radiation fields, and hence the treatment fields should be tailored according to 
each individual. Other studies (19) also reported that there was significant 
decline in diffusion capacity and total lung volume in patients treated with 
irradiation for esophageal cancer.  
 
In a study from MD Anderson Cancer Center (20) , 110 patients were 
treated with preoperative chemoradiation, and the mean lung dose, effective 
dose and absolute lung dose receiving  less than or equal to 5Gy were calculated 
which proved to predict the risk of developing postoperative pulmonary 
complications. In this, 18% developed pulmonary complications, with higher 
rates when the V10 values were more than or equal to 40%   (35% vs 8%) and 
V15 values of more than or equal to 30% (33% vs 11%). The authors concluded 
that minimization of irradiated lung volumes led to reduced postoperative 
pulmonary complications.  This increase in postoperative pulmonary 
complications  like pneumonitis, acute respiratory distress syndrome, when V10 
value was more than 40% suggest that volume of remaining or undamaged lung 
tissue may predict postoperative pulmonary complications. In other words, 
patients with smaller lung volume  to begin with will experience higher rates of 
postoperative pulmonary complications. Also patients with less functional 
reserve may be more susceptible to postoperative pulmonary complications. 
Hence, it is essential to calculate total lung volume in addition to dose volume 
histogram.  
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A chinese study (21) evaluated patients receiving chemoradiotherapy 
followed by resection showed that volume of lung sparing more than or equal   
5 Gy was the only predicitive independent dosimetric factor in analyzing 
postoperative pulmonary complications. Wang et al described that the relative 
V5 of all volumes spared from 5 Gy to 35 Gy correlated significantly with the 
incidence of postoperative pulmonary complications,  although on multivariate 
analyses, V5 proved to be the only significant predictive prognostic factor, 
indicating that the volume of unexposed lung  during induction therapy was 
predictive. The majority of patients in this study were treated with induction 
chemotherapy, mostly paclitaxel, which had shown to increase the rate of 
pneumonitis in other sites. A significant association of induction chemotherapy 
prior to concurrent chemoradiotherapy was found to be a predictive factor for 
Grade 2 or greater pneumonitis (48% vs 13% respectively). Hence, it concluded 
that, induction chemotherapy alone will sensitize lung tissue to radiation 
damage. Compared to this, another study evaluated 98 patients, who received 
preoperative chemoradiotherapy with 5-FU and cisplatin followed by surgery 
had no significant postoperative pulmonary complications leading to the 
conclusion that neoadjuvantchemoradiation had no detrimental effect in lung 
toxicity. Finally, a Taiwanese study (23) using IMRT in esophageal cancer 
evaluated the preoperative forced expiratory volume in one second (FEV1) and 
showed that it was a significant independent predictive factor, and that reducing 
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the absolute dose to the right lung might reduce the incidence of significant 
postoperative pulmonary complications.  
 
Radiation induced cardiac toxicity: 
Radiation induced cardiac toxicity involves injury to numerous structures 
like pericardium, which manifests as effusion or pericarditis, coronary arteries, 
heart muscle fibres, cardiac valves, or nerve and conduction defects. Radiation 
mainly leads to fibrosis or small vessel injury. Classic radiation tolerance values 
i.e TD 5/5 for the heart is about 60 Gy when the irradiated volume is less than 
or equal to 25%. Similarly, TD 5/5 is 45 Gy when the irradiated volume is about 
65%. The mechanism that leads to cardiac injury especially in esophageal 
cancer is poorly defined. Historically, treated patients with Hodgkin's disease 
who received more than 40 Gy led to increased cardiac morbidity and mortality. 
Roughly, V30 of more than 46% predicts an increased risk of having pericardial 
effusion leading to increased cardiac morbidity. Also, there was reports stating 
that increased V20 dose to left ventricle led to decrease in ejection fraction, and 
thereby functioning of the heart.  
 
Pulmonary function testing: 
Pulmonary function test (PFT) is a complete battery of tests that involves 
patient history, Clinical examination, Chest X-ray, Arterial Blood gas analysis 
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and tests of pulmonary function. It is done mainly to assess the functional 
integrity of lungs and to understand the severity of pulmonary function 
impairment. It has both diagnostic and therapeutic roles and usually done by a 
separate technician. 
Lung volumes: 
Lung volumes (23) and lung capacities are associated with different phases 
of respiratory cycle. Lung volumes are directly calculated, and lung capacities 
are inferred from the same. The average lung capacity for an adult male is about 
6 litres of air. Among this, only a few percentage is used for normal breathing. 
The average respiratory rate is about 30-60 breaths per minute at birth, reducing 
to around 12-20 in adult. Some of the lung volumes that are measured are: 
 Total lung capacity (TLC): This is the measured volume of lungs at 
maximal inflation, this is the sum of both residual volumes and vital 
capacity.  
 Tidal volume(TV) is the volume of air that moves in and out during quiet 
breathing.  
 Residual volume (RV) is the volume of air that remains after a maximal 
expiration. 
 Expiratory reserve volume (ERV) is the volume of air that can be exhaled 
from end expiratory position. 
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 Inspiratory Reserve voume(IRV) is maximal volume of air that can be 
inhaled from end inspiratory level.  
 Inspiratory capacity (IC) is the sum of inspiratory reserve volume and 
tidal  volume. 
 Vital capacity (VC) is the volume of air exhaled after maximum 
inspiration.  
 Inspiratory vital capacity (IVC) is the maximum volume of air inhaled 
after maximum expiration.  
 Functional residual capacity (FRC) is the volume of lungs at end 
expiratory position. 
 Forced vital capacity (FVC) is the vital capacity that is measured after a 
maximal forced expiratory effort.  
 Forced expiratory volume (FEV1) is the volume of air exhaled at the first 
second of forced expiration.  
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Type Examples Volumes FEV1/FVC 
Restrictive Interstitial lung 
disease 
Volumes are 
decreased 
In normal range 
(0.8-1.0) 
Obstructive COPD,Asthma Volumes are 
normal but flow 
rates decreased 
Reduced (<0.8) 
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Indications for Pulmonary Function Testing: 
 Neuromuscular disorders like Duchenne Muscular dystrophy 
 Chronic dyspnea 
 Asthma  
 Preoperative testing 
 COPD 
 Restrictive lung diseases 
 Disability or functional impairment 
 
Spirometry: 
Spirometry measures Forced vital capacity, Forced expiratory volume 
FEV1,Forced inspiratory flow rates, etc. By measuring these volumes, 
spirometry assess the ability of lungs to move air in and out through the airways 
to identify any airway obstruction or restriction.  
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By spirometry, a pneumotachograph is obtained, with which lung 
conditions like cystic fibrosis, asthma, COPD, pulmonary fibrosis, interstitial 
lung diseases etc can be identified. It may be also used for diagnosing bronchial 
hyperresponsiveness to cold air, exercise or drugs.  
 
Complications of spirometryinclude syncope, chest pain, paroxysomal 
cough, pneumothorax, nosocomial infections, increased intracranial pressure, 
oxygen desaturation and bronchospasm.  
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3.ORIGIN OF THE STUDY: 
Our institute records about 350esophageal cancers per year; among which 
only 50% of the cases are treated due to various factors.  Most of the esophageal 
cancers present with advanced stage at diagnosis. The treatment modality 
includes either definitive chemoradiation; neoadjuvant chemoradiation followed 
by surgery or Surgery followed by postoperative adjuvant chemoradiation. As 
esophagus is a thoracic and abdominal structure, many of the vital structures 
come into the field of radiation, and hence, in this modern era of radiation 
oncology, using sophisticated techniques like the conformal or IMRT have 
become the modality of choice to deliver radiation, so that, treatment is planned 
by avoiding dose to the surrounding normal tissues. On such contexts, 
delivering techniques like IMRT will not be feasible in all places, due to costs 
and other factors. In places like our institute, where number  of patients treated 
per day per machine is high, treating all patients with IMRT will not be an ideal 
strategy. Also, due to the high integral dose in IMRT, low dose irradiation to 
normal tissues might pose a  significant health hazard, along with the fact, long 
term data for IMRT is not available. Hence, the concept of Hybrid conformal 
technique arose, where tumours can be treated with a better intent of reducing 
the integral dose, time taken for treatment, without compromising on the dose 
distribution.  
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4.AIM OF THE STUDY: 
To assess the feasibility of Hybrid conformal technique in treatment of 
Esophageal cancers thereby achieving a non inferior dose distribution to that of 
IMRT, to reduce the volume of lung treated, and also to calculate the time taken 
for both.  
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5.MATERIALS AND METHODS: 
Patients:  
Twenty patients were considered for this prospective study. Patients were 
planned for both Hybrid conformal and IMRT techniques from the year 
December 2013 to September 2014 and their dose volume histograms were 
calculated. Patient characteristics are as given in the following table. 
Gender (Male : Female) 12:8 
Dose 54Gy 
Chemotherapy 7 patients  
Total lung volume  3800cc 
Ipsilateral lung volume 2000cc 
Contralateral lung volume 1800cc 
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Female
40%
Male
60%
Gender
35%
65%
Chemoradiation and Radiation
Concurrent
EBRT
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Inclusion Criteria: 
1. Age 35-75 years  
2. Both Sexes  
3. Histology-Squamous cell carcinoma  
4. Carcinomas of thoracic Esophagus 
5. Concurrent Chemotherapy  
6. Radiation Therapy alone  
7. ECOG Performance status 0,1 and 2.  
8. Patient who do not have metastatic disease  
9. Patients with adequate bone marrow function defined as Absolute 
peripheral Granulocye count of >2000 cells/mm3; platelet count of 
>100000 cells/mm3; adequate hepatic function with Serum Bilirubin 
<1.5mg/dl; Serum Creatinine<1.5mg/dl;creatinine clearance of >50 
ml/min; SGOT or SGPT <2x the normal; and normal Serum Calcium.  
 
Exclusion Criteria: 
1. Patients with prior irradiation to Chest  
2. Histology-Non Squamous cell carcinoma  
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3. Carcinoma of Cervical Esophagus and involving OG junction.  
4. Age<35 and >75 years  
5. Metastatic Carcinoma Esophagus 
6. Patients with bone marrow suppression, abnormal renal and liver function 
tests, Creatinine clearance of <50ml/min; and low serum calcium.  
7. Patients with  ischemic heart disease or myocardial infarction.  
8. Pregnant women.  
9. Patients with simultaneous primaries.  
 
Contouring: 
All patients underwent CT scans with 5mm slices during normal 
breathing. No specific measures were taken to control respiratory movements. 
This was subsequently followed by delineating the gross tumour volume, for 
which Clinical target volume was made. Furthermore, Planning Target volume 
(PTV) were drawn with a superior and inferior margin of 5cm and radial margin 
of 2-2.5cm were done. The spinal cord, heart, left and right lungs were 
contoured. Patients also underwent Pulmonary function testing before start of 
the treatment, so that basic functioning of lungs can be assessed and compared 
at the end of treatment.  
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GROSS TUMOUR VOLUME 
CLINICAL TARGET VOLUME 
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GROSS TUMOUR VOLUME 
CLINICAL TARGET VOLUME 
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PLANNING TARGET VOLUME 
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Dose Prescription and Planning technique: 
Treatment planning was done with the help of Varian treatment planning 
systems. Dose calculations were done with the help of Analytical Anisotropic 
Algorithm(AAA). Then planning was done for both hybrid conformal and 
IMRT techniques. Hybrid conformal technique consists of static beams that 
delivers half the dose of radiation with the help of two opposing 
Anteroposterior-Posteroanterior fields, followed by conformal technique which 
delivers the remaining dose. Approximately, the two opposing fields were given 
upto a total dose of 30 Gy followed by conformal technique which delivers the 
remaining 24 Gy with the same PTV thereby totalling to a dose of about 54 Gy. 
Literature reviews indicate a treatment dose of about 50-50.4 Gy. But based on 
our Institute protocol, treatment were delivered to a total dose of 54 Gy. Daily 
doses were given with 200cGy per fraction per day.  
 
Anteroposterior and posteroanterior fields, as the name suggests, were 
treated with two opposing fields, followed by conformal technique. Conformal 
technique were delivered with the help of four field technique, with 
minimization of lung volumes. Comparing to this, an all-IMRT plan was made 
with the help of seven to eight fields, thereby achieving the target volume, 
minimizing the doses to normal tissues. IMRT beams were oriented in such a 
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way that the beams are non opposed and at different angles, thereby avoiding 
the spinal cord. It is illustrated below.  
 
 
 
2-OPPOSING AP/PA 
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CONFORMAL TECHNIQUE WITH THREE OF FOUR FIELDS 
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IMRT 
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Dose volume histograms are then calculated for both the planning target 
volume (PTV) and organ at risk. The MLD, volume of lung receiving 20 Gy 
(V20) for both lungs and mean dose to heart are calculated. It is compared with 
Hybrid Conformal technique and assessed. V30 for heart is also noted.  
 
Patients then are treated with two opposing anteroposterior and 
posteroanterior fields,upto a total dose of 30 Gy followed by conformal 
technique upto a TD of 54 Gy. Those patients who receive concurrent 
chemotherapy are treated with three weekly cisplatin with a dose of 70mg/m2 or 
weekly cisplatin with a dose of 40mg/m2. Patients are carefully noted for side 
effects of radiation like esophagitis, mucositis, pneumonitis, chest pain,dyspnea 
or bone marrow suppression. After completion of treatment, patients again are 
subjected to  pulmonary function testing and compared with the initial values.  
 
Patient Outcomes: 
Patients are advised to review after six weeks initially and then followed 
up at monthly intervals.  
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6.RESULTS: 
Patient characteristics: 
Among the twenty patients treated, twelve patients were males and eight 
patients were females. Out of them, twelve patients were carcinomas of middle 
thoracic  esophagus, six involve upper thoracic esophagus and two belong to 
lower thoracic esophagus without involving gastroesophageal junction. All 
these patients underwent Hybrid conformal technique and were also planned for 
all-IMRT plans. Patients also underwent pulmonary function testing both before 
and after treatment. Among the twenty patients, thirteen patients are treated 
only with radiation therapy and seven patients received concurrent 
chemoradiation. Out of the chemotherapy patients, four patients received three 
weekly cisplatin and three patients received weekly cisplatin due to their 
biological tolerance.  
 
Dose volume histogram of these twenty patients were analyzed 
extensively and found that dose distribution attained by Hybrid conformal 
technique was not at all inferior when compared to that of IMRT plans. IMRT, 
being a modern superior technique achieved a uniformal dose distribution for all 
these patients, confined to the planning  target volume. On the other hand, in 
Hybrid conformal technique, dose distribution achieved in planning target 
68 
 
volume was not inferior to that of IMRT plans, achieving the same dose without 
compromising the tumour volume.  
 
There was no incidence of pneumonitis in any of these patients. The V20 
calculated were less than 30% in all these patients. The lung dose was 
calculated by taking into account the combination of both right and left lungs. 
Both Hybrid conformal and IMRT plans were able to achieve a V20 value of 
less than 30%. Also, the mean lung dose for both Hybrid conformal and IMRT 
techniques were less than 20 Gy. But noting the difference in both these 
techniques, Hybrid conformal technique achieved a much lesser lung dose 
compared to the all-IMRT plan in both V20 as well as mean lung dose. It 
showed that both V20 and mean lung dose achieved in Hybrid conformal 
technique was atleast 5% lesser in V20, and atleast 1 to 2 Gy lesser than IMRT 
plans.  
 
No of Patients V20 Hybrid conformal(%) V20 IMRT(%) 
1 16.52 18.66 
2 12.22 19.95 
3 13.32 22.78 
4 16.03 22.98 
5 12.46 15.71 
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6 12.81 17.67 
7 15.93 24.50 
8 10.26 22.33 
9 17.88 19.88 
10 16.86 18.73 
11 15.77 18.42 
12 16.12 19.18 
13 15.87 18.06 
14 12.12 16.55 
15 14.66 19.14 
16 16.97 20.81 
17 13.86 18.88 
18 16.11 20.08 
19 14.76 19.66 
20 13.12 17.84 
 
 
 
No of Patients MLD Hybrid 
conformal(Gy) 
MLD IMRT (Gy) 
1 15.18 16.42 
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2 12.31 14.67 
3 10.98 14.48 
4 11.93 16.05 
5 10.73 11.48 
6 11.55 17.55 
7 15.10 18.08 
8 11.85 14.44 
9 16.83 18.01 
10 14.22 15.42 
11 11.88 13.88 
12 14.12 16.56 
13 13.88 16.68 
14 10.04 13.88 
15 12.81 16.14 
16 13.16 14.22 
17 11.88 16.56 
18 14.06 18.51 
19 12.64 17.81 
20 12.08 15.67 
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The cord dose achieved in IMRT is much lesser than than the usual 
constraint of 45Gy point dose. Similarly, the cord dose achieved in Hybrid 
conformal technique was much higher than that of IMRT, but still being 
achieved with in a dose of 45Gy.  
 
No of Patients Cord dose Hybrid 
conformal(Gy) 
Cord dose IMRT (Gy) 
1 44.98 41.16 
2 44.48 40.20 
3 44.72 40.35 
4 43.77 42.79 
5 44..32 41.87 
6 44.55 40.88 
7 44.37 41.86 
8 45.01 42.60 
9 44.67 40.45 
10 43.89 40.04 
11 43.98 40.01 
12 44.95 41.11 
13 44.86 39.96 
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14 43.86 41.01 
15 44.44 40.90 
16 43.98 42.22 
17 45.04 43.97 
18 44.87 40.05 
19 43.78 41.87 
20 43.98 42.05 
 
The other main organ at risk in the treatment field is heart, which usually 
is in the plane of treatment. The mean dose to heart for these twenty patients 
under study were less than 30 Gy. The V30 calculated for the heart is less than 
the usual constraint of 46Gy.  
No of 
Patients 
Heart mean dose  
Hybrid conformal (Gy) 
Heart mean dose 
 IMRT (Gy) 
1 30.87 28.25 
2 24.32 26.55 
3 26.07 24.03 
4 25.36 24.22 
5 20.21 18.88 
6 23.85 21.91 
7 29.82 27.25 
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8 29.91 27.71 
9 30.44 28.61 
10 26.88 24.14 
11 28.88 25.82 
12 29.76 28.85 
13 26.82 25.96 
14 27.68 26.52 
15 29.86 27.98 
16 23.67 22.86 
17 25.52 24.42 
18 26.87 25.76 
19 27.12 26.01 
20 28.84 26.04 
 
Pulmonary function testing was done both before and after treatment. The 
twenty patients under consideration had no abnormal deviation of pulmonary 
function testing, except for one patient, who had restrictive pattern even before 
treatment which has not worsened during the course of treatment. Patient had 
the same restrictive pattern even before and after treatment. Summarizing these, 
the Dose volume histograms for both Hybrid conformal and IMRT fields are as 
follows: 
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7.DISCUSSION: 
Treatment of Esophageal cancer is a challenging task for any radiation 
oncologist; treatment of any patient does not stop with patient alone, it goes a 
step further by rehabilitating the patient. It is because, Esophageal cancers, 
many of the times, are silent at early stages, usually providing vague symptoms 
like dyspepsia, belching, gastritis, dysphagia etc. The Classic symptom of 
dysphagiamay not present initially, it usually presents at later stages and hence 
most of the esophageal cancers present late at diagnosis. Furthermore, local 
control, disease free survival(DFS), progression free survival (PFS), and overall 
survival (OS) at 2 and 5 years are usually less compared to other cancers. There 
is only a 20-30% overall survival benefit at 5 years with concurrent 
chemoradiation and less than 10% survival benefit with radiation therapy alone. 
Hence, expecting and treating side effects of therapy is a must which might 
improve the quality of life.  
 
One of the most important and under looked side effect of radiation 
therapy in Carcinoma Esophagus is the incidence of Radiation induced 
pneumonitis. Radiation pneumonitis poses a significant challenge for any 
radiation oncologist whose treatment fields involve radiation dosage to lungs. 
Studies have always tried to find out the relationship and incidence of 
pneumonitis while irradiating the lung tissues either as primary, or secondary to 
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other carcinomas. Almost all the studies evaluated have shown that V20 values 
less than or equal to 30% is universally acceptable, according to QUANTEC 
dosimetric analysis, and hence, have always tried to maintain the lung dosage 
within such limits. Increased lung doses have been associated with increased 
incidence of radiation pneumonitis, though not in every case. There is an high 
chance of radiation pneumonitis in patients who undergo higher modern 
sophisticated techniques like the IMRT, due to the low dose to the normal 
tissues which interprets as increased lung dose. At the same time, dose to the 
tumour volume is better achieved with IMRT because, IMRT can be planned in 
such a way so that even in abnormal dose distributions, IMRT can achieve the 
homogenous uniformal dose distribution that is expected.  
Intensity modulated radiotherapy can achieve target dose better than 
conventional and conformal therapies; along with the reduction of normal tissue 
doses. Even though, the long term morbidity data for IMRT has to be proven 
because of the potential disadvantage of higher integral dose and irradiating low 
doses to the normal structures due to the various beamlets. Taking into 
consideration, Hybrid conformal therapy takes into account, combination of 
both conventional technique and conformal therapy. It is superior to conformal 
therapy alone in a way that the treatment for patient can be started as early as 
possible with two opposing anteroposterior and posteroanterior fields. Also, one 
of the approaches to treat esophagus has been the treatment of Hybrid 
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techniques with two opposing fields delivered upto half or two-thirds of total 
dosage, with the remaining doses being delivered either with conformal or 
IMRT techniques. This approach is followed because of the potential risk of 
myelopathy when the spinal cord is irradiated beyond 45 to 50 Gy. 
 
Dose volume histograms comparing both Hybrid conformal and IMRT 
techniques in twenty patients suggest that tumour dose in Hybrid conformal 
technique achieved is not inferior compared to IMRT. Without compromising 
the tumour dose, the lung doses were calculated in both arms. The lung doses 
calculated with both the mean doses and V20 show that, in all twenty patients, 
V20 achieved is at least 5% lesser than that of IMRT; taking into fact that both 
these techniques achieve lung dosage constraint of less than 30 %. Similarly, 
mean lung dose achieved between these two techniques in all the twenty 
patients reveal that, doses achieved in Hybrid conformal technique is nearly one 
to two Gy lesser than that achieved in IMRT. This may be attributed to the fact 
that IMRT, even though is based on inverse planning, has larger beamlets and 
subfields, and hence delivers low dose radiation to normal tissues. This is 
particularly important, because of the fact that it might lead to an increase in the 
incidence of secondary malignancies.  
 
79 
 
These values were statistically calculated to find out the statistical 
significance of the findings between both these arms. Both the mean dose to the 
lungs and volume of lungs receiving less than twenty Gray, were assessed 
statistically using independent t-test analysis, and it was found that the dose 
values in Hybrid conformal technique was lesser and was statistically 
significant compared to Intensity modulated radiotherapy with a p-value of less 
than 0.05. Hence, there was a significant difference statistically with the lung 
dose values trending towards a safer range with the technique under study, 
which might help in reducing complications. The following pictorial 
represention has dose percentage in y-axis and number of patients under x-axis, 
thereby comparing the V20 between Hybrid conformal and IMRT.  
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It can be better represented so that the V20 achieved will be comparable 
and is statistically significant. The blue line indicates the V20 values for twenty 
patients for Hybrid conformal technique and the red line indicates the same for 
IMRT.  
 
 
The mean lung doses for Hybrid Conformal technique and IMRT are 
given below in this bar diagram with x-axis representing the number of patients 
and y-axis representing dose values measured in Gray.  
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Mean dose to heart was also calculated between both Hybrid conformal 
and IMRT techniques. The values suggested that heart doses were lesser with 
IMRT compared to Hybrid conformal technique, but not significant to that of 
IMRT. It has to be seen whether the increased heart dose will present as 
pericarditis or other cardiac complications has to be seen.  
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Spinal cord dose constraint was kept into consideration in each and every 
patient, as the risk of developing myelopathy was always  borne in mind, 
considering the fact, myelopathy is the deadliest complication that will paralyze 
the patient leading to disability  thereby adversely affecting his or her quality of 
life. Both Hybrid conformal and Intensity  modulated Radiotherapy techniques 
were planned so that all the twenty patients were receiving less than 45 Gy. 
IMRT plans achieved cord dose better due to its inverse planning, but was not 
very significant compared to Hybrid conformal technique. The latter was able to 
achieve the cord dose just like IMRT with just a higher margin, but within the 
constraint dose of 45 Gy. This significantly reduces the morbidity of increased 
cord dose, thereby keeping in line with the dose constraints.
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The time taken for each technique was also noted. It was calculated 
starting from the entry of patient, to setup, and then deliver radiation till exit of 
the patient from the machine unit was assessed. The time taken for IMRT was 
around 17 to 20 minutes for each patient, compared to Hybrid conformal 
technique which took around 5 to 7 minutes for setup and delivery of the 
treatment. In the same context, two opposing, as expected, had lesser time 
duration than conformal technique, both of which, were much lesser when 
compared to IMRT. 
 
Treatment delivery times usually are least considered when treatment 
modality is taken into account. But in places where daily patient turnover is 
very high, and the number of patients treated per day per machine is higher, 
treatment delivery times are considered to improve the efficiency and efficacy 
of treatment delivered. But at the same time, tumour dose volume should never 
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be compromised so that the patient is never under treated for his ailment. 
Reducing the time duration for each patient will considerably reduce the 
treatment times and hence patients can be treated without  long waiting times. 
 
Another factor for consideration of Hybrid conformal over IMRT is that, 
in Indian setup, many patients cannot afford the increased cost of treatment with 
IMRT. In such cases, a cheaper alternative that does not compromise tumor 
dose is required. Hybrid conformal technique will be fulfilling that fact and will 
be a very good alternative with additional benefits of sparing the lung volumes.  
 
Pulmonary function tests used assess the function of lungs and to know 
about the severity of any lung impairment. Among the twenty patients studied, 
one patient had a restrictive lung pattern even before start of the treatment, and 
had the same value at the end of treatment. None of these patients had any 
incidence of pulmonary toxicity clinically, and hence at the end of treatment, 
almost all had the same values as pre treatment pulmonary function testing. 
There was no difference or change with the FEV1, FVC, Tidal volume or lung 
capacity with both pre treatment and post treatment testing. Even if pulmonary 
function testing done before and after treatment does not show any significant 
difference with Hybrid conformal technique, it cannot be confirmed that there is 
no incidence of radiation induced pneumonitis with Hybrid conformal, because, 
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pneumonitis is a clinical entity, and at least take around two to six months to 
develop post treatment. Hence, long term follow up data is required for both 
Hybrid conformal and IMRT technique to assess the incidence of pneumonitis, 
and pulmonary function testing at follow-up will be able to pick out the 
incidence of lung dysfunction at an earlier stage. To add to this, patients who 
are treated with irradiation whose treatment fields include lungs as organs at 
risk, pulmonary function testing can be made mandatory to assess the real 
incidence of treatment induced clinical symptoms of pneumonitis, which if 
done, can pick up earlier dysfunctions so that tackling of radiation induced 
pneumonitis can be easier for the treating physician.  
 
One study (24) evaluated the incidence of radiation pneumonitis with 
increasing age. They compared younger age with advanced age patients with 
lung cancer, treated with irradiation involving thoracic fields. The study actually 
took into account 256 patients having both Stage I-III small cell and non small 
cell cancer, treated with irradiation with or without concurrent chemotherapy. 
The study showed that seventy patients were elderly, more than 70 years old 
and one hundred and fifty seven patients were less than 70 years old. Among 
them 30% of patients had grade II pneumonitis, 10% had Grade III pneumonitis 
and 1 to 2% of patients had Grade IV pneumonitis. The study concluded that 
Elderly patients are more vulnerable for radiation induced lung toxicity. Dose 
parameters like the V20, mean lung dose etc will help in assessing the toxicity, 
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but the threshold for clinical evidence of pneumonitis may be much lower than 
when compared with younger patients, matching other confounding factors 
available.  
 
In another study (25), non small cell lung cancer patients who are treated 
with radiation therapy were taken into consideration and the risk of pneumonitis 
was noted. The study assessed the right parameter to assess the risk of radiation 
pneumonitis which might correlate clinically. It took into account 98 patients 
who were inoperable and were treated with definitive irradiation. Dose volume 
histograms were drawn and the parameters that are usually calculated like V5, 
V10, V20, mean lung dose, total lung volume, separate volumes etc are drawn 
and assessed. The risk of radiation pneumonitis   especially Grade 2 
pneumonitis increased steadily in these patients treated with irradiation. It was 
seen that, these patients had higher V20 values, was found to be statistically 
significant (p<0.05) and it was concluded that V20 may be one of the main 
deciding parameter in evaluation of lung toxicity in patients treated with 
irradiation.  
 
Similarly, a Chinese study evaluated the risk of therapy induced 
pneumonitis in non small cell lung cancer patients treated with concurrent 
chemoradiation. The study analyzed 220 patients treated with concurrent 
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chemoradiation and were followed up for a period of 10 months. It calculated 
the dosimetric analyses by using Dose volume histograms and calculated V5, 
V10, V15, V20 upto V60 in 5 Gy increments along with mean lung dose, lung 
volumes etc. The study correlated that incidence of radiation induced 
pneumonitis was evident with increase in V5 values itself. The results of this 
study also showed that values apart from V5, like V10, V20 etc also was 
associated with increase in incidence of pneumonitis. Analysis using 
multivariate logarithm showed that relative V5 values were associated with one 
year increased incidence of radiation associated pneumonitis. Many of these 
patients had Grade III pneumonitis, and the associated relative V5 value was 
kept to a value of 42%. Those patients who had  a V5 of less than 42% had a 
3% risk of radiation induced pneumonitis. On the contrary, the study reported 
that V5 value of more than 42% had a 39% increase in incidence of radiation 
linked pneumonitis. This led to the conclusion that relative V5 values are linked 
to a higher incidence of radiation induced pneumonitis, but may not be taken as 
the sole predictive factor until further evidences prove the same in randomized 
controlled trials.  
 
One of the main study (26) that combined Hybrid technique was the study 
done in University of Massachusetts Medical school which compared Hybrid 
IMRT with other techniques. The study actually compared Hybrid IMRT that 
consists of static and dynamic beams which included IMRT technique for both 
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esophagus and lung cancer patients and to assess a way to reduce the volume of 
lungs treated with the technique along with delivering a conformal dose 
distribution.  
This study took into account eighteen patients, twelve of which were lung 
cancers ( both small and non small cell cancers) and six esophageal cancer 
patients treated between February 2005 to December 2006 spanning for a period 
of nearly two years. The study included static beams consisting of two opposing 
anteroposterior and posteroanterior fields for nearly two-thirds of dose and 
IMRT which included one third of dose given in combination that constituted 
the Hybrid IMRT. For comparison, the study took into account, conformal 
technique, a four field IMRT technique, five field IMRT technique, and a 
equally spaced nine field IMRT technique. The study carefully assessed the 
volume of lungs treated at different levels. This also included the naming of 
lungs as ipsilateral and contralateral; i.e, the lung that is receiving the maximum 
dose near the tumour was coined as ipsilateral and the opposite as contralateral 
lung volume. Dose volume histograms were drawn and was calculated for heart, 
lungs both ipsilateral, contralateral, total; and planning target volume. The plans 
calculated V5, V13, V20, V30 lung volumes, along with mean lung dose and 
Equivalent uniform dose.  
Results of this trial showed that lung doses that were achieved with 
Hybrid IMRT were lesser, especially with V5, V13 and V20 volumes. It was 
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found that there was a larger reduction in this technique which combined static 
and dynamic beams that led to this reduction. Conversely, the comparison plans 
led to a higher lung volume, especially with V5 values which were reduced by 5 
points in Hybrid IMRT. The V13 was reduced nearly by 3.5 points and the V20 
volume were atleast 11 percent lower than nine field sophisticated IMRT plan. 
Similarly, the volumes calculated, outperformed four and five field IMRT plans 
by a significant margin. But, conformal beam therapy led to lesser volume of 
lung being treated, but it was not statistically significant compared to Hybrid 
plans.  
Finally, the authors concluded that treating patients with Hybrid plans 
and not an extensive IMRT plan, reduced the volume of lung treated due to the 
low doses imparted by the entry of beamlets with IMRT technique. This led to 
reduction of low dose lung volume to the lungs, that resulted in significant 
decrease of lung mean dose atleast less than 13 Gy. This value was significant, 
as most of the studies compared and came to a conclusion that the values less 
than 13 Gy led to significant decrease in lung morbidity. Also, the authors tried 
their justification of their use of IMRT to one-third of dosage, because of the 
reduction of intrafraction motion that can be reduced only by gating, and hence 
reducing the error by means of using static beams to two-thirds of dosage. 
Finally, the patients under this study, did not encounter any radiation induced 
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morbidity that led to this technique, being non inferior to any of the other 
techniques that were taken into comparison.  
 
The above mentioned study justified the superiority of usage of Hybrid 
techniques by means of four following explanations. They are as follows.  
 Reduction of low dose lung volume that is a part of exclusive IMRT 
techniques. Hybrid techniques align the primary beams with two-
opposing anteroposterior and posteroanterior axis, that led to the 
coverage of tumour volume. Hence, there was no compromise with the 
target volume, and IMRT boosted the primary beams thereby achieving a 
better tumour control, with reduction of lung doses.  
 Secondly, dose errors due to patient motion. The thorax is the main site 
where motion due to respiration has to be taken into account. This leads 
to the fact, that IMRT plans, which have precise dose targets, will surely 
have intrafraction errors due to respiration. This can lead to under-dosage 
of target thereby leading to compromisation of tumour volume. This is 
reduced with Hybrid techniques, which reduces the IMRT planning 
thereby leading to reduction of these errors.  
 Thirdly, the planning algorithms used in planning systems. It is found 
that, there is a greater error with beams that are highly sophisticated like 
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the pencil beams. IMRT uses such techniques, and these can be reduced 
further with Hybrid techniques.  
 Fourth and not least, not every radiation oncologist are convinced with 
the IMRT plans, and due to the paucity of data that is available for their 
long term effects, and hence, this technique involves a plan that is 
between a conventional style and a sophisticated one.  
Other studies like the presentation in American Society of theraputic 
Radiology and Oncology (ASTRO) that held in 2004, showed similar results. 
This study assessed the risk of Radiation pneumonitis, which was mentioned 
with a grade 3 or more as classified by the Radiation Therapy Oncology group, 
by correlating with the dosimetric factors of heart, lung and its subregions.  
 
This study retrospectively calculated and correlated the risk of radiation 
pneumonitis. Their patients had Grade 3 or more pneumonitis, and dosimetric 
analysis showed that V5, V10 and V13  to the ipsilateral and contralateral lungs 
were more linked with the risk of radiation pneumonitis. Hence the study 
concluded that, volume of lungs like V5, V10 and V13 were more linked with 
the risk factor more than V20, and hence concluded that incidence of radiation 
pneumonitis is more with these factors.  
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A chinese study (28) in 2005, analyzed the clinical and dosimetric factors 
that was asssociated with treatment related pneumonitis in patients with non 
small cell lung cancer. This study analyzed two hundred and twenty patients 
with non small cell lung cancer treated with concurrent chemoradiation.  This 
study concluded that V5 volumes were more linked with the risk of therapy 
associated pneumonitis. V5 values less than 42 percent were associated with 
three percent increased risk which showed  an increase to about 40%, when the 
same volume was associated with more than 42 percent.  
 
Similarly, another chinese study assessed the incidence of postoperative 
pulmonary complications in patients with esophageal cancer by calculating the 
clinical and dosimetric factors who were treated with concurrent 
chemoradiation followed by surgery.  
 
The above mentioned study took into account 110 patients with esophageal 
cancers treated from January 1998 to December 2003 over a span of five years. 
All patients underwent three dimensional conformal radiotherapy along with 
concurrent chemotherapy. Chemotherapy given was either 5-Fluorouracil or 
irinotecan based; with the radiation delivered upto a TD of 41.4 to 50.4 Gy. 
These patients then underwent surgery either by transthoracic or transhiatal 
esophageal techniques. The surgery was timed after thiry days upto 120 days 
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after chemoradiation. Dose volume histograms were drawn which calculated 
lung volumes, mean dose to lungs, mean dose to heart, etc. Endpoints were 
decided with the incidence of postoperative pulmonary complications like acute 
respiratory distress syndrome or pneumonitis that occurred one month after 
surgery. It was found that eighteen patients from the study group had incidence 
of radiation pneumonitis. All these patients, on retrospective analysis, found 
that,V5, V10, V20, mean dose to lungs etc were were increased compared to the 
normal patients. The values associated with the increased lung doses were 
proportionate to the incidence of postoperative pulmonary complications. Also, 
compared to other volumes, V5 was associated with significant appearance of 
postoperative pulmonary complications.  Hence this study concluded that, less 
dose to lungs, as evident by the reduced V5 values, might reduce the incidence 
of postoperative pulmonary complications.  
 
Studies from the Mayo Clinic (25), tried to find out the dosimetric and 
clinical parameters that will be helpful to assess the incidence of radiation 
pneumonitis  after radiation to the thoracic sites. This study analyzed 
retrospectively the incidence of Grade 2 or more radiation pneumonitis in 
patients with thoracic cancers. Dose volume histograms were drawn which 
analyzed Total lung volume along with the gross tumour volume, along with the 
MLD, V5, V10, V13, V20 and were calculated using regression analysis. 
Among the 92 patients studied, twelve patients presented with clinical 
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symptoms of radiation pneumonitis. Analysis showed that all these twelve 
patients had higher V5, V10, V13, V20, MLD, and Total lung minus gross 
tumour volumes. It was also seen that V10 and V13 were better predictors for 
radiation pneumonitis. The authors concluded that Intrathoracic radiotherapy 
should be cautiously and judiciously approached by the radiation oncologists 
while delivering a higher lung volume which are fraught with complications.  
 
Studies from Japan (29) showed the causality between the incidence of 
radiation pneumonitis after twice daily hyperfractionation along with 
chemotherapy in patients with Stage III non small cell lung cancer. 37 patients 
were considered for this study and was treated with twice daily fractionation of 
1.2 Gy upto a TD of 60 Gy along with chemotherapy which included paclitaxel 
and carboplatin regimens. Dose volume histogram was drawn adn values were 
analyzed.  
 
It was seen that, fourteen of thirty seven patients were having Grade II or 
worse pneumonitis. It was seen that all patients with V5 more than 40%, 
patients with V10 more than 35%, patients with V13 more than 33%, and V20 
more than 24% were associated with increased incidence of radiation induced 
pneumonitis. The remaining patients had lower Vdose values and hence had 
lower incidence of pneumonitis. Also, the mean lung dose which was calculated 
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as more than 15 Gy in 8 patients were found to have more incidence of 
pneumontis, compared to those patients who had less than 15 Gy had a lesser 
incidence of radiation induced pneumonitis. The authors concluded that these 
cut-off values will be more useful in assessing the risk associated with the 
incidence of radiation induced pneumonitis in patients treated with concurrent 
chemoradiation, even including hyperfractionation.  
 
In this study, the dose to the planning target volume was calculated for both 
Hybrid conformal and IMRT techniques. It was seen that, the dose achieved by 
IMRT technique was superior, but at the same time, dose achieved by Hybrid 
conformal technique to the target volume was not inferior compared to the 
control technique. Moreover, the time taken for both these techniques to deliver 
treatment, varies significantly, as IMRT takes around 17 to 20 minutes to 
deliver treatment, whereas, Hybrid conformal technique takes about 5 to 7 
minutes to complete the procedure. Hence, there is less waiting time compared 
and faster treatment delivery, which reduces the irradiation time to the patient.  
 
The lung doses that is delivered via Hybrid conformal technique and the 
IMRT are compared extensively, where the volumes as well as the mean dose to 
the lungs are calculated. It is seen that, V20 received in Hybrid conformal 
technique was atleast 5 percent lower than IMRT which used seven fields. The 
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values achieved in these twenty patients were analyzed using independent t-test, 
and was found to be statistically significant with a p-value of less than 0.05.  
 
Similarly, the MLD i.e. mean lung dose calculated in these twenty patients, 
were atleast one to two Gy lower in Hybrid conformal technique, compared to 
the seven to eight fields IMRT. This was also statistically analyzed using 
independent t-test, and was again found to be statistically significant having a p-
value of less than 0.05. This proves that, Hybrid conformal technique, which is 
a mixture of static two-opposing anteroposterior and posteroanterior shaper 
fields for half the tumour dose, followed by conformal therapy by using three to 
four field technique for the reminder of the tumour dose. This in comparison, 
with an all-IMRT shows that, Hybrid conformal delivers much less dose to the 
normal tissue, whereas, IMRT delivers low dose volume to the lungs thereby 
resulting in higher integral dose, leading to higher V20 and mean dose to the 
lungs. This in turn, will reduce the theoretical incidence of secondary 
malignancies.  
 
Furthermore,  all these patients, underwent pulmonary function tests before 
and after treatment. Apart from one patient, the rest of the nineteen patients did 
not have a significant difference in their FEV1/FVC ratio. Even in that one 
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patient, who had changes, it was the same restrictive pattern both before and 
after radiation.  
 
The result based on pulmonary function tests has two potential limitations: 
one, the test has to be done in follow-ups of  one, two and six months, as the 
risk of clinical incidence of pneumonitis can be seen only after one to six 
months of radiation. Second, the test has to be done in IMRT arm, after delivery 
of the technique, which can show the true incidence of clinically signifcant 
pneumonitis. This in turn,  has to be calculated for a period of before and after 
treatment, one, two and six months of follow-up.  
 
Mean dose to the heart was also calculated, and it was found that, IMRT 
technique had a better chance of reducing the heart dose, but this difference was 
not significant when compared to that of Hybrid conformal technique, as the 
difference was low, and that, heart has a better tolerance limit compared to that 
of lung. 
The dose to spinal cord was achieved in both techniques. IMRT, being a 
sophisticated technique, and a technique based on inverse planning, performs 
better in such cases to control the constraints. But at the same time, Hybrid 
conformal was able to achieve the same dose constraint, given the tolerance 
dose to spinal cord. Even though, IMRT achieved constraints like 40 Gy in one 
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case and 43 in another case, Hybrid conformal was able to achieve a constraint 
of less than 45 Gy in all cases, and hence the difference will not be statistically 
significant. Since this organ is based on series relationship rather than parallel, 
the dose constraint if less than 45 Gy is more than enough to prevent the 
incidence of myelopathy. Given the concept of reirradiation, at which point, 
IMRT doses are not much less compared to that of Hybrid conformal technique, 
and hence, won't be able to spare as much as cord as it is thought of.  
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8.CONCLUSION:  
Hybrid conformal technique has potential advantages over IMRT such 
that it reduces the low dose volume to the normal tissues, thereby minimising 
the integral dose. It also eliminates the effects of patient's motion which affects 
IMRT in a great way, because, the margin for error in IMRT has always been 
very less. In Indian scenario, there is patient-cost factor which also plays a 
dominant part in deciding treatment modalities. In our country, not all patients 
can afford IMRT, and at the same time, IMRT is not justified in all patients, as 
many patients will not require such sophisticated techniques. In places, where 
techniques like Hybrid conformal can be used, it can virtually replace IMRT 
because of the potential reduction of side effects like radiation induced 
pneumonitis. This in turn, will reduce the incidence of postoperative pulmonary 
complications, which is usually reflected as pneumonitis and acute respiratory 
distress syndrome. Hence, this will lead to reduction of side effects, which 
ultimately reflects as better quality of life.  Finally, there is a lack of potential 
data for long term side effects for IMRT. Till that is known, IMRT cannot be 
made the standard of choice, and hence, techniques like Hybrid conformal 
which has  a better side effect profile and non inferior dose distribution with a 
better treatment time can be used, that will further avoid postoperative 
pulmonary complications. Even if the lung doses are avoided by Hybrid 
conformal technique, long term follow up data is required to assess the clinical 
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incidence of pneumonitis, which along with non inferior uniformal dose 
distribution can be a boon to any radiation oncologist in the near future.   
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